Lindis Blood Care

Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood collected during the operation. The product consists of a combination of an antibody and filter and serves to remove cancer cells from the blood.

Press releases

Press
9. February 2022

Lindis Blood Care successfully closes follow-on financing round 

Funding round supported by High-Tech Gründerfonds (HTGF), Brandenburg Kapital and several private investors, showing their continued commitmentFunds to be mainly used to complete ongoing REMOVE study with CATUVAB®, extend clinical program, complete CE marking procedure, start FDA market application process and support partnering activitiesCATUVAB® is a novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood Hennigsdorf, Germa
 
Press
11. December 2019
Over 5 Million Euros For Lindis Blood Care: Development Of A New Product For The Removal Of Tumor Cells From Surgical Blood
Clinical development of the product CATUVAB secured CATUVAB is designed to enable tumor cell free return of autologous blood collected during a surgery without significantly altering standard surgical procedures High-Tech Gründerfonds (HTGF), Brandenburg Kapital and five private investors participated in a capital increase Including the ILB grants from the "ProFIT" program of the European Regional Development Fund (3.3 million euros), the Company receives a total of more than 5 million
 

Address

Neuendorfstraße 20B
16761 Hennigsdorf
Deutschland

In portfolio

23. Sep 2019

HTGF Manager

Dr. Angelika Vlachou, Principal / Authorized Signatory